We assessed the in vivo efficacy of Dynole 34-2 for human AML using xenograft models carrying oncogenic mutations of either FLT3 or KRAS, as these genetic lesions are amongst the most common activating mutations of growth factor-induced signalling pathways found in AML at diagnosis (around 25% and 15% of cases, respectively)61. Here, FLT3 is linked to acute myeloid leukemia.